文献速递艾滋病与性传播感染

多拉韦林联合拉替拉韦每日一次口服转换治疗HIV-1抑制患者的2期随机试验

Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL).
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

DORAL是一项在法国、意大利和西班牙开展的多中心、开放标签、随机2期试验,评估病毒学抑制的HIV-1感染者转换为多拉韦林(100 mg)联合拉替拉韦(1200 mg)每日一次口服两药方案的有效性和安全性。114名参与者按2:1随机分为立即转换组或延迟转换组(继续基线ART至第48周后转换)。第48周立即转换组发生1例病毒学失败(1.3%;95%CI 0.0-6.9),延迟转换组无病毒学失败;至第96周无新增病毒学失败,免疫学参数稳定,3例因药物相关不良事件停药。

要点

  • 病毒学抑制的HIV-1感染者转换为多拉韦林+拉替拉韦每日一次两药方案,第48周病毒学失败率低。
  • 至第96周无新增病毒学失败,免疫学参数保持稳定。
  • 3例因多拉韦林和拉替拉韦相关不良事件导致治疗中断,1例3级焦虑与研究治疗相关。

核心结论

  • 这项概念验证性2期转换试验支持在特定HIV-1感染者中使用多拉韦林联合拉替拉韦每日一次两药方案的可行性,尤其当需要最小化药物相互作用或避免NRTI暴露时。

研究设计与样本

  • DORAL为在法国、意大利和西班牙开展的多中心、开放标签、随机2期试验。
  • 114名病毒学抑制的成人HIV感染者(接受稳定ART、未使用过多拉韦林、无拉替拉韦耐药)按2:1随机分为立即转换组(多拉韦林100 mg+拉替拉韦1200 mg每日一次)或延迟转换组(继续基线ART至第48周后转换)。
  • 主要终点为第48周病毒学失败(确认血浆HIV-1-RNA≥50 copies/mL)。

主要发现

  • 参与者中位年龄57岁,中位CD4计数700 cells/mm3,中位病毒学抑制持续时间10年。
  • 第48周立即转换组发生1例病毒学失败(1.3%;95%CI 0.0-6.9),延迟转换组无病毒学失败。
  • 至第96周无新增病毒学失败,随访期间免疫学参数保持稳定。
  • 3例被认为与多拉韦林和拉替拉韦相关的不良事件导致治疗中断,报告1例与研究治疗相关的3级不良事件(焦虑)。
  • 生殖道亚研究中大多数样本药物浓度超过抑制阈值,精液HIV-1-RNA低水平检出少见。

临床怎么用

  • 在特定病毒学抑制的HIV-1感染者中,可考虑多拉韦林联合拉替拉韦每日一次两药方案作为转换选项,尤其当需要最小化药物相互作用或避免NRTI暴露时。

局限性

  • 本研究为2期概念验证性试验,样本量有限(114例),需更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the efficacy and safety of a once-daily oral two-drug regimen (2DR) combining doravirine and raltegravir in virologically suppressed people with HIV (PWH). METHODS: DORAL is a multicentre, open-label, randomized phase II trial conducted in France, Italy, and Spain. Virologically suppressed adults receiving stable antiretroviral therapy (ART), naïve to doravirine and without raltegravir resistance, were randomized (2:1) either to switch immediately to doravirine (100 mg) plus raltegravir (1200 mg) or to continue baseline ART until week 48 before switching to doravirine plus raltegravir. The primary endpoint was virological failure (VF; confirmed plasma HIV-1-RNA ≥50 copies/mL) at week 48. Secondary endpoints included maintenance of virological suppression through W96, immunological outcomes, safety, and pharmacokinetics in a genital sub-study. RESULTS: Among 114 participants (median age, 57 years; median CD4 count, 700 cells/mm3; median duration of virological suppression, 10 years), one VF occurred by week 48 in the immediate-switch group (1.3%; 95% CI, 0.0-6.9); none occurred in the delayed-switch group. No additional VF was observed through week 96. Immunological parameters remained stable during follow-up. Three adverse events considered related to doravirine and raltegravir led to treatment discontinuation. One grade 3 adverse event (anxiety), considered related to study treatment, was reported. In the genital sub-study, drug concentrations exceeded inhibitory thresholds in most samples, with infrequent detection of low-level seminal HIV-1-RNA. CONCLUSIONS: This proof-of-concept phase II switch trial supports the feasibility of a once-daily doravirine plus raltegravir 2DR in selected PWH, particularly when minimizing drug-drug interactions or avoiding NRTI exposure is a priority.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Palich R, Lê MP, Castagna A, et al. Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL). J Antimicrob Chemother. 2026. PMID: 42841932. doi:10.1093/jac/dkag336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。